Analyze Diet

Topic:Vaccine development

Vaccine development in horses involves the creation and refinement of immunizations to protect equine populations from infectious diseases. This process includes identifying antigens, formulating vaccines, and evaluating their safety and efficacy through clinical trials. Vaccines stimulate the horse's immune system to recognize and combat specific pathogens, thereby reducing the incidence and severity of diseases. Common equine vaccines target diseases such as equine influenza, tetanus, and West Nile virus. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, challenges, and advancements in vaccine development for equine health.
Safety and immunogenicity of a sarcoid vaccine in horses.
Journal of equine veterinary science    February 10, 2025   Volume 146 105381 doi: 10.1016/j.jevs.2025.105381
Jacob O, Hause B, Peters-Smith K, Adam EN, Page AE, Floyd C, Tucker C, Eertink LG, Wang D, Li F.Equine sarcoids are the most identified skin tumors of horses, which are highly associated with bovine papillomavirus infection. Sarcoids can impair the use of the horse and are difficult to treat, resulting in significant economic losses and a welfare concern. There is no vaccine available to protect global equines from sarcoids. We aimed to determine the safety and protective antibody response in horses immunized with a recombinant baculovirus vector vaccine expressing the L1 protein of bovine papillomavirus type 1 (BPV1). A group of 10 clinically healthy, sarcoid-free horses were immunized ...
Eastern equine encephalitis virus: Pathogenesis, immune response, and clinical manifestations.
Infectious medicine    January 17, 2025   Volume 4, Issue 1 100167 doi: 10.1016/j.imj.2025.100167
Parashar B, Malviya R, Sridhar SB, Wadhwa T, Talath S, Shareef J.Eastern equine encephalitis virus (EEEV) is a lethal transmitted by mosquitoes that primarily cycles between birds. Although rare, infections in humans and horses are associated with high mortality rates and severe neurological effects. Climate change appears to be increasing the spread of this virus. This study aims to provide a comprehensive analysis of EEEV, including its transmission dynamics, pathogenesis, induced host immune response, and long-term impacts on survivors. It also highlights the virus's unique immune evasion strategies that complicate disease management and contribute to ...
Multiple Gene Deletion Mutants of Equine Herpesvirus 1 Exhibit Strong Protective Efficacy Against Wild Virus Challenge in a Murine Model.
Vaccines    January 8, 2025   Volume 13, Issue 1 45 doi: 10.3390/vaccines13010045
Pradhan SS, Balena V, Bera BC, Anand T, Khetmalis R, Madhwal A, Kandasamy S, Pavulraj S, Bernela M, Mor P, Tripathi BN, Virmani N.Equine herpesvirus type 1 (EHV1) is a ubiquitous viral pathogen infecting the equine population worldwide. EHV1 infection causes respiratory illness, abortion, neonatal foal mortality, and myeloencephalopathy. The currently available modified live EHV1 vaccines have safety and efficacy limitations. The two mutant EHV1 viruses (vToH-DMV (∆IR6/gE) and vToH-QMV (∆IR6/UL43/gE/UL56)), generated by the deletion of genes responsible for virulence (gE and IR6) and immunosuppression (uL43 and uL56), have been previously characterized by our group and found to generate good immune responses. The pre...
West Nile Virus: An Update Focusing on Southern Europe.
Microorganisms    December 18, 2024   Volume 12, Issue 12 2623 doi: 10.3390/microorganisms12122623
Carrasco L, Utrilla MJ, Fuentes-Romero B, Fernandez-Novo A, Martin-Maldonado B.West Nile Virus (WNV) is a zoonotic, vector-borne pathogen affecting humans and animals, particularly in Europe. The virus is primarily transmitted through mosquitoes that infect birds, which serve as the main reservoirs. Humans and horses are incidental hosts. This review focuses on the epidemiology of WNV in southern Europe, particularly its increasing prevalence. Methods included an extensive literature review and analysis of recent outbreaks. WNV is largely asymptomatic in humans, but a small percentage can develop West Nile neuroinvasive disease (WNND), leading to severe neurological symp...
Immunization but not natural infection of horses results in antibody activity against the S protein of Streptococcus equi subsp equi.
American journal of veterinary research    December 16, 2024   1-11 doi: 10.2460/ajvr.24.08.0228
Cohen ND, Hughes EV, Bayne C, Morris ERA, Bray JM, Landrock KK, Gonzales DM, Baker RM, Klein RL, Liu W, Legere RM, Wehmeyer SG, Bordin AI....Evaluate the immunogenicity of a vaccine targeting the S protein (Ssee) of Streptococcus equi subsp equi and determine antibody activity against Ssee in horses with strangles. Methods: The study was designed as a prospective experiment using 20 university-owned Quarter Horses and a cross-sectional serosurvey of 78 privately owned horses with strangles. Horses were immunized IM with 0 (n = 4), 200 (n = 8), or 400 (n = 8) μg of recombinant Ssee at weeks 0, 4, and 12. Serum and nasal secretions were collected at weeks 0, 4, 6, 12, 16, and 28 and tested by ELISA for immunoglobulin (Ig)-G against ...
Immunization but not natural infection of horses results in antibody activity against the S protein of Streptococcus equi subsp equi.
American journal of veterinary research    December 16, 2024   1-11 doi: 10.2460/ajvr.24.08.0228
Cohen ND, Hughes EV, Bayne C, Morris ERA, Bray JM, Landrock KK, Gonzales DM, Baker RM, Klein RL, Liu W, Legere RM, Wehmeyer SG, Bordin AI....Evaluate the immunogenicity of a vaccine targeting the S protein (Ssee) of Streptococcus equi subsp equi and determine antibody activity against Ssee in horses with strangles. Methods: The study was designed as a prospective experiment using 20 university-owned Quarter Horses and a cross-sectional serosurvey of 78 privately owned horses with strangles. Horses were immunized IM with 0 (n = 4), 200 (n = 8), or 400 (n = 8) μg of recombinant Ssee at weeks 0, 4, and 12. Serum and nasal secretions were collected at weeks 0, 4, 6, 12, 16, and 28 and tested by ELISA for immunoglobulin (Ig)-G against ...
Genetic, Phylogenetic, and Serological Analysis of a Getah Virus Strain Isolated from Culex tritaeniorhynchus Mosquitoes in Nagasaki, Japan in 2022.
Japanese journal of infectious diseases    November 29, 2024   Volume 78, Issue 2 71-78 doi: 10.7883/yoken.JJID.2024.250
Matsumura R, Bannai H, Nemoto M, Higa Y, Kai I, Sasaki T, Futami K, Yoshikawa A, Fujita R, Hino M, Nagata K, Kuwata R, Kaku Y, Kobayashi D....Getah virus (GETV), belonging to the genus Alphavirus within the family Togaviridae, is a mosquito-borne virus that causes fever, rash, edema in horses, fatalities, and pregnancy disorders in pigs. It has caused occasional outbreaks in horse populations in Japan, China, and India, and the endemic areas are gradually expanding, particularly in Asia and Oceania. In this study, we isolated a new GETV strain from Culex tritaeniorhynchus mosquitoes collected in Nagasaki Prefecture, Japan, in 2022. Phylogenetic analysis demonstrated that this new strain, 22IH8, was more closely related to previous C...
Attenuated Getah virus confers protection against multiple arthritogenic alphaviruses.
PLoS pathogens    November 18, 2024   Volume 20, Issue 11 e1012700 doi: 10.1371/journal.ppat.1012700
Jiang Z, Merits A, Qin Y, Xing G, Zhang L, Chen J, Wang N, Varjak M, Zhai X, Li D, Song W, Su S.Alphaviruses are important arthropod-transmitted pathogens of humans and livestock. Getah virus (GETV) is an arthritogenic alphavirus that causes disease in horses and piglets; it also poses a potential threat to humans. A live attenuated vaccine candidate named GETV-3ΔS2-CM1, harbouring a deletion in nonstructural protein 3 and substitutions in the capsid protein, is genetically stable and exhibits robust immunogenicity. It was shown to confer passive protection to piglets born to immunized sows. In mice, a single dose of GETV-3ΔS2-CM1 protected against infection with different strains of G...
Antibody isotyping and cytokine profiling in natural cases of Burkholderia mallei infection (glanders) in equines.
Cytokine    November 16, 2024   Volume 185 156799 doi: 10.1016/j.cyto.2024.156799
Pooja , Thapa N, Rani R, Shanmugasundaram K, Jhandai P, Rakshita , Bhattacharya TK, Singha H.Immunological aspects of B. mallei infection were rarely studied in natural cases of equines. The present study was conducted to determine IgG, IgM, IgA and IgG (T) titre against recombinant Hcp1, TssA and TssB proteins and PilA-Hcp1-TssN-BipD and BpaB-BpaC- BMAA0553 chimeras and cytokine responses in glanders affected equine serum. Methods: The study was conducted on serum samples collected from 151 glanders positive equines which include horses (n = 134), mules (n = 16), and donkeys (n = 01). The IgM, IgG, IgA and IgG (T) titre were determined against recombinant antigens by indirect E...
Allergen immunotherapy using recombinant Culicoides allergens improves clinical signs of equine insect bite hypersensitivity.
Frontiers in allergy    September 30, 2024   Volume 5 1467245 doi: 10.3389/falgy.2024.1467245
Graner A, Mueller RS, Geisler J, Bogenstätter D, White SJ, Jonsdottir S, Marti E.Insect bite hypersensitivity (IBH) is an IgE-mediated allergic dermatitis of horses caused by bites of spp., sharing some common features with human atopic dermatitis. Allergen immunotherapy (AIT) using whole-body extracts has limited efficacy. This study aimed to evaluate AIT with a pool of major recombinant allergens in a prospective, double-blinded, placebo-controlled study. Unassigned: The IBH lesion score was assessed during a pre-treatment year and first treatment year (May-October) in 17 horses and in May and July of a second treatment year. Nine horses were immunized subcutaneously ...
A platform for the rapid screening of equine immunoglobins F (ab)2 derived from single equine memory B cells able to cross-neutralize to influenza virus.
Emerging microbes & infections    September 27, 2024   Volume 13, Issue 1 2396864 doi: 10.1080/22221751.2024.2396864
Lin Y, Wang Y, Li H, Liu T, Zhang J, Guo X, Guo W, Wang Y, Liu X, Huang S, Liao H, Wang X.Single B cells-based antibody platforms offer an effective approach for the discovery of useful antibodies for therapeutic or research purposes. Here we present a method for screening equine immunoglobins F(ab)2, which offers the potential advantage of reacting with multiple epitopes on the virus. Using equine influenza virus (EIV) as model, a hemagglutinin (HA) trimer was constructed to bait B cells in vaccinated horses. We screened 370 HA-specific B cells from 1 × 10 PBMCs and identified a diverse set of equine variable region gene sequences of heavy and light chains and then recombined wit...
Identification of three novel linear B-cell epitopes on VP7 of African horse sickness virus using monoclonal antibodies.
Veterinary microbiology    September 23, 2024   Volume 298 110258 doi: 10.1016/j.vetmic.2024.110258
Hu X, Xu J, Wang X, Tian Z, Guan G, Luo J, Yin H, Du J.African horse sickness (AHS) is an acute and subacute infectious disease of equine species caused by the African horse sickness virus (AHSV). The VP7 of AHSV is a group-specific protein conserved in all serotypes and is an excellent candidate for the serological diagnosis and an AHS vaccine component. However, to date, B-cell epitopes on the AHSV VP7 recognized by humoral immune responses remain unclear. This study expressed the recombinant AHSV VP7 soluble in Escherichia coli and purified it for mouse immunization. Four monoclonal antibodies (mAbs) were screened and identified by hybridoma ce...
Breaking Latent Infection: How ORF37/38-Deletion Mutants Offer New Hope against EHV-1 Neuropathogenicity.
Viruses    September 16, 2024   Volume 16, Issue 9 1472 doi: 10.3390/v16091472
Hu Y, Zhang SY, Sun WC, Feng YR, Gong HR, Ran DL, Zhang BZ, Liu JH.Equid alphaherpesvirus 1 (EHV-1) has been linked to the emergence of neurological disorders, with the horse racing industry experiencing significant impacts from outbreaks of equine herpesvirus myeloencephalopathy (EHM). Building robust immune memory before pathogen exposure enables rapid recognition and elimination, preventing infection. This is crucial for effectively managing EHV-1. Removing neuropathogenic factors and immune evasion genes to develop live attenuated vaccines appears to be a successful strategy for EHV-1 vaccines. We created mutant viruses without ORF38 and ORF37/38 and vali...
Protective immune response against Rhodococcus equi: An innate immunity-focused review.
Equine veterinary journal    September 11, 2024   doi: 10.1111/evj.14214
da Silveira BP, Cohen ND, Lawhon SD, Watson RO, Bordin AI.Rhodococcus equi causes pyogranulomatous pneumonia in foals and immunocompromised people. Despite decades of research efforts, no vaccine is available against this common cause of disease and death in foals. The purpose of this narrative review is to summarise the current understanding of interactions between R. equi and the host innate immune system, to describe features of the immune response that are associated with resistance or susceptibility to R. equi infection, and help guide strategies for developing novel approaches for preventing R. equi infections. Virulence of R. equi in foals has...
Impact of equine herpesvirus-1 ORF15 (EUL45) on viral replication and neurovirulence.
Veterinary microbiology    August 22, 2024   Volume 298 110234 doi: 10.1016/j.vetmic.2024.110234
Kasem S, Yu MHH, Alkhalefa N, Ata EB, Nayel M, Abdo W, Abdel-Moneim AS, Fukushi H.Equine herpesvirus 1 (EHV-1) causes respiratory illness, fetal loss, perinatal mortality, and myeloencephalopathy. This study investigated ORF15's impact on virus infectivity and neurovirulence. The Ab4p neurovirulent strain of EHV1 was used as a backbone to create Ab4p attB, Ab4p∆ORF15, and Ab4p∆ORF15R chimeras via BAC DNA transfection into RK-13 cells. Viral growth kinetics, plaque size, transcription, and growth were assessed in MDBK cells, mouse neurons, and fetal equine brain cells. Neurovirulence was evaluated post-intranasal inoculation into male CBA/N1 SPF mice, measuring signs, vi...
Immune horses rapidly increase antileukoproteinase and lack type I interferon secretion during mucosal innate immune responses against equine herpesvirus type 1.
Microbiology spectrum    August 20, 2024   Volume 12, Issue 10 e0109224 doi: 10.1128/spectrum.01092-24
Holmes CM, Babasyan S, Eady N, Schnabel CL, Wagner B.Equine herpesvirus type 1 (EHV-1) is one of the most prevalent respiratory pathogens in horses with a high impact on animal health worldwide. Entry of the virus into epithelial cells of the upper respiratory tract and rapid local viral replication is followed by infection of local lymphoid tissues leading to cell-associated viremia and disease progression. Pre-existing mucosal immunity has previously been shown to reduce viral shedding and prevent viremia, consequently limiting severe disease manifestations. Here, nasopharyngeal transcriptomic profiling was used to identify differentially expr...
Science-in-brief: The 6th Havemeyer Workshop on Rhodococcus equi-A decade-long journey in advancing research into a major equine pathogen (2012-2023).
Equine veterinary journal    August 8, 2024   Volume 56, Issue 5 838-841 doi: 10.1111/evj.14135
No abstract available
Antibody reactions of horses against various domains of the EHV-1 receptor-binding protein gD1.
PloS one    July 12, 2024   Volume 19, Issue 7 e0301987 doi: 10.1371/journal.pone.0301987
Schramm A, Ackermann M, Eichwald C, Aguilar C, Fraefel C, Lechmann J.Equid alphaherpesviruses 1 (EHV-1) and 4 (EHV-4) are closely related and both endemic in horses worldwide. Both viruses replicate in the upper respiratory tract, but EHV-1 may additionally lead to abortion and equine herpesvirus myeloencephalopathy (EHM). We focused on antibody responses in horses against the receptor-binding glycoprotein D of EHV-1 (gD1), which shares a 77% amino acid identity with its counterpart in EHV-4 (gD4). Both antigens give rise to cross-reacting antibodies, including neutralizing antibodies. However, immunity against EHV-4 is not considered protective against EHM. Wh...
Development of a live attenuated vaccine candidate for equid alphaherpesvirus 1 control: a step towards efficient protection.
Frontiers in immunology    July 3, 2024   Volume 15 1408510 doi: 10.3389/fimmu.2024.1408510
Hu Y, Wu G, Jia Q, Zhang B, Sun W, Sa R, Zhang S, Cai W, Jarhen , Ran D, Liu J.Equid alphaherpesvirus 1 (EqAHV1) is a viral pathogen known to cause respiratory disease, neurologic syndromes, and abortion storms in horses. Currently, there are no vaccines that provide complete protection against EqAHV1. Marker vaccines and the differentiation of infected and vaccinated animals (DIVA) strategy are effective for preventing and controlling outbreaks but have not been used for the prevention of EqAHV1 infection. Glycoprotein 2 (gp2), located on the envelope of viruses (EqAHV1), exhibits high antigenicity and functions as a molecular marker for DIVA. In this study, a series of...
Bacillus toyonensis amplifies the immunogenicity of an experimental recombinant tetanus vaccine in horses.
Journal of equine veterinary science    June 22, 2024   Volume 140 105135 doi: 10.1016/j.jevs.2024.105135
Abreu MC, Conrad NL, Gonçalves VS, Leite FPL.Probiotic microorganisms can stimulate an immune response and increase the efficiency of vaccines. For example, Bacillus toyonensis is a nonpathogenic, Gram-positive bacterium that has been used as a probiotic in animal supplementation. It induces immunomodulatory effects and increases the vaccine response in several species. This study aimed to evaluate the effect of B. toyonensis supplementation on the modulation of the immune response in horses vaccinated with recombinant Clostridium tetani toxin. Twenty horses were vaccinated twice, with an interval of 21 days between doses, and equally di...
The Potential of Plant-Produced Virus-like Particle Vaccines for African Horse Sickness and Other Equine Orbiviruses.
Pathogens (Basel, Switzerland)    May 28, 2024   Volume 13, Issue 6 458 doi: 10.3390/pathogens13060458
Pitchers KG, Boakye OD, Campeotto I, Daly JM.African horse sickness is a devastating viral disease of equids. It is transmitted by biting midges of the genus with mortalities reaching over 90% in naïve horses. It is endemic to sub-Saharan Africa and is seasonally endemic in many parts of southern Africa. However, outbreaks in Europe and Asia have occurred that caused significant economic issues. There are attenuated vaccines available for control of the virus but concerns regarding the safety and efficacy means that alternatives are sought. One promising alternative is the use of virus-like particles in vaccine preparations, which have...
Impact of the host immune response on the development of equine herpesvirus myeloencephalopathy in horses.
The Journal of general virology    May 20, 2024   Volume 105, Issue 5 doi: 10.1099/jgv.0.001987
Giessler KS, Goehring LS, Jacob SI, Davis A, Esser MM, Lee Y, Zarski LM, Weber PSD, Hussey GS.Herpesviruses establish a well-adapted balance with their host's immune system. Despite this co-evolutionary balance, infections can lead to severe disease including neurological disorders in their natural host. In horses, equine herpesvirus 1 (EHV-1) causes respiratory disease, abortions, neonatal foal death and myeloencephalopathy (EHM) in ~10 % of acute infections worldwide. Many aspects of EHM pathogenesis and protection from EHM are still poorly understood. However, it has been shown that the incidence of EHM increases to >70 % in female horses >20 years of age. In this study we use...
Equine herpesvirus type 1 (EHV-1) replication at the upper respiratory entry site is inhibited by neutralizing EHV-1-specific IgG1 and IgG4/7 mucosal antibodies.
Journal of virology    May 14, 2024   Volume 98, Issue 6 e0025024 doi: 10.1128/jvi.00250-24
Eady NA, Holmes C, Schnabel C, Babasyan S, Wagner B.Equine herpesvirus type 1 (EHV-1) is a contagious respiratory pathogen that infects the mucosa of the upper respiratory tract (URT). Mucosal immune responses at the URT provide the first line of defense against EHV-1 and are crucial for orchestrating immunity. To define host-pathogen interactions, we characterized B-cell responses, antibody isotype functions, and EHV-1 replication of susceptible (non-immune) and clinically protected (immune) horses after experimental EHV-1 infection. Nasal secretion and nasal wash samples were collected and used for the isolation of DNA, RNA, and mucosal antib...
Lessons Learned from West Nile Virus Infection:Vaccinations in Equines and Their Implications for One Health Approaches.
Viruses    May 14, 2024   Volume 16, Issue 5 781 doi: 10.3390/v16050781
Naveed A, Eertink LG, Wang D, Li F.Humans and equines are two dead-end hosts of the mosquito-borne West Nile virus (WNV) with similar susceptibility and pathogenesis. Since the introduction of WNV vaccines into equine populations of the United States of America (USA) in late 2002, there have been only sporadic cases of WNV infection in equines. These cases are generally attributed to unvaccinated and under-vaccinated equines. In contrast, due to the lack of a human WNV vaccine, WNV cases in humans have remained steadily high. An average of 115 deaths have been reported per year in the USA since the first reported case in 1999. ...
Expression of IL-10 and TGF-β1 in horses experimentally infected with T. equi merozoites is associated with antibody production but not modulation of pro-inflammatory responses.
Frontiers in immunology    May 13, 2024   Volume 15 1370255 doi: 10.3389/fimmu.2024.1370255
Onzere CK, Bastos RG, Bishop RP, Suarez CE, Fry LM. () is an apicomplexan parasite that causes severe hemolytic anemia in equids. Presently, there is inadequate knowledge of the immune responses induced by in equid hosts impeding understanding of the host parasite relationship and development of potent vaccines for control of infections. The objective of this study was to evaluate the host-parasite dynamics between merozoites and infected horses by assessing cytokine expression during primary and secondary parasite exposure, and to determine whether the pattern of expression correlated with clinical indicators of disease. Our findings showe...
Identification of equine mares as reservoir hosts for pathogenic species of Leptospira.
Frontiers in veterinary science    May 9, 2024   Volume 11 1346713 doi: 10.3389/fvets.2024.1346713
Hamond C, Adam EN, Stone NE, LeCount K, Anderson T, Putz EJ, Camp P, Hicks J, Stuber T, van der Linden H, Bayles DO, Sahl JW, Schlater LK, Wagner DM....Equine leptospirosis can result in abortion, stillbirth, neonatal death, placentitis, and uveitis. Horses can also act as subclinical reservoir hosts of infection, which are characterized as asymptomatic carriers that persistently excrete leptospires and transmit disease. In this study, PCR and culture were used to assess urinary shedding of pathogenic Leptospira from 37 asymptomatic mares. Three asymptomatic mares, designated as H2, H8, and H9, were PCR-positive for lipL32, a gene specific for pathogenic species of Leptospira. One asymptomatic mare, H9, was culture-positive, and the recovered...
Development of novel Streptococcus equi vaccines with an assessment of their immunizing potentials and protective efficacies.
BMC veterinary research    May 3, 2024   Volume 20, Issue 1 173 doi: 10.1186/s12917-024-04012-z
Soliman R, Yousef M, Gelil SA, Aboul-Ella H.Strangles is a highly contagious disease of the equine upper respiratory tract caused by Streptococcus equi subspecies. Streptococcus equi subsp. equi (S. equi) and Streptococcus equi subsp. zooepidemicus (S. zooepidemicus) was isolated, as local, hot, and field strains, from horses clinically suffering from respiratory distress. The isolated Streptococci were identified using bacteriological and molecular techniques. Four formulations of inactivated S. equi vaccines were developed and evaluated. The first formulation was prepared using the S. equi isolates, adjuvanted with MONTANIDE GEL adjuv...
Vaccination and Control Methods of West Nile Virus Infection in Equids and Humans.
Vaccines    May 1, 2024   Volume 12, Issue 5 485 doi: 10.3390/vaccines12050485
Cendejas PM, Goodman AG.West Nile virus (WNV) is capable of causing severe neurologic disease in both humans and equines, making it a disease of importance in both human medicine and veterinary medicine. No targeted treatments exist for WNV infection in either humans or equines. Infection is treated symptomatically through management of symptoms like fever and seizures. As treatment for WNV is purely supportive, the response to WNV has focused primarily on methods of disease prevention. To this end, research efforts have yielded several effective vaccines for equine use as well as numerous conventional mosquito contr...
Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice.
PloS one    April 16, 2024   Volume 19, Issue 4 e0301340 doi: 10.1371/journal.pone.0301340
O'Kennedy MM, Roth R, Ebersohn K, du Plessis LH, Mamputha S, Rutkowska DA, du Preez I, Verschoor JA, Lemmer Y.A safe, highly immunogenic multivalent vaccine to protect against all nine serotypes of African horse sickness virus (AHSV), will revolutionise the AHS vaccine industry in endemic countries and beyond. Plant-produced AHS virus-like particles (VLPs) and soluble viral protein 2 (VP2) vaccine candidates were developed that have the potential to protect against all nine serotypes but can equally well be formulated as mono- and bi-valent formulations for localised outbreaks of specific serotypes. In the first interferon α/β receptor knock-out (IFNAR-/-) mice trial conducted, a nine-serotype (nona...
Development and Validation of Three Triplex Real-Time RT-PCR Assays for Typing African Horse Sickness Virus: Utility for Disease Control and Other Laboratory Applications.
Viruses    March 20, 2024   Volume 16, Issue 3 470 doi: 10.3390/v16030470
Villalba R, Tena-Tomás C, Ruano MJ, Valero-Lorenzo M, López-Herranz A, Cano-Gómez C, Agüero M.The African horse sickness virus (AHSV) belongs to the Genus Orbivirus, family Sedoreoviridae, and nine serotypes of the virus have been described to date. The AHSV genome is composed of ten linear segments of double-stranded (ds) RNA, numbered in decreasing size order (Seg-1 to Seg-10). Genome segment 2 (Seg-2) encodes outer-capsid protein VP2, the most variable AHSV protein and the primary target for neutralizing antibodies. Consequently, Seg-2 determines the identity of the virus serotype. An African horse sickness (AHS) outbreak in an AHS-free status country requires identifying the seroty...